BACKGROUND: Total laryngectomy remains the treatment of choice for recurrent/persistent laryngeal squamous cell carcinoma (SCC) after radiotherapy (RT) or chemoradiotherapy (CRT). However, despite attempts at aggressive surgical salvage, survival in this cohort remains suboptimal. METHODS: A prospectively maintained single-institution database was queried for patients undergoing total laryngectomy for recurrent/persistent laryngeal SCC after initial RT/CRT between 1998 and 2015(n = 244). Demographic, clinical, and survival data were abstracted. The Kaplan-Meier survival curves and hazard ratios (HRs) were calculated. RESULTS: Five-year overall survival (OS) was 49%. Five-year disease-free survival (DFS) was 58%. Independent predictors of OS included severe comorbidity (Adult Comorbidity Evaluation-27 [ACE-27] scale; HR 3.76; 95% confidence interval [CI] 1.56-9.06), and positive recurrent clinical nodes (HR 2.91; 95% CI 1.74-4.88). CONCLUSION: Severe comorbidity status is the strongest predictor of OS, suggesting that increased attention to mitigating competing risks to health is critical. These data may inform a risk prediction model to allow for focused shared decision making, preoperative health optimization, and patient selection for adjuvant therapies.
BACKGROUND: Total laryngectomy remains the treatment of choice for recurrent/persistent laryngeal squamous cell carcinoma (SCC) after radiotherapy (RT) or chemoradiotherapy (CRT). However, despite attempts at aggressive surgical salvage, survival in this cohort remains suboptimal. METHODS: A prospectively maintained single-institution database was queried for patients undergoing total laryngectomy for recurrent/persistent laryngeal SCC after initial RT/CRT between 1998 and 2015(n = 244). Demographic, clinical, and survival data were abstracted. The Kaplan-Meier survival curves and hazard ratios (HRs) were calculated. RESULTS: Five-year overall survival (OS) was 49%. Five-year disease-free survival (DFS) was 58%. Independent predictors of OS included severe comorbidity (Adult Comorbidity Evaluation-27 [ACE-27] scale; HR 3.76; 95% confidence interval [CI] 1.56-9.06), and positive recurrent clinical nodes (HR 2.91; 95% CI 1.74-4.88). CONCLUSION: Severe comorbidity status is the strongest predictor of OS, suggesting that increased attention to mitigating competing risks to health is critical. These data may inform a risk prediction model to allow for focused shared decision making, preoperative health optimization, and patient selection for adjuvant therapies.
Authors: Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson Journal: N Engl J Med Date: 1991-06-13 Impact factor: 91.245
Authors: Vlad C Sandulache; Laura J Vandelaar; Heath D Skinner; Juan Cata; Katherine Hutcheson; Clifton David Fuller; Jack Phan; Zuhair Siddiqui; Stephen Y Lai; Randal S Weber; Mark E Zafereo Journal: Head Neck Date: 2016-02-16 Impact factor: 3.147
Authors: Andrew C Birkeland; Andrew J Rosko; Mohamad R Issa; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Otolaryngol Head Neck Surg Date: 2016-02-16 Impact factor: 3.497
Authors: Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Andrew C Birkeland; Megan Yanik; Brittny N Tillman; Megan V Scott; Susan K Foltin; Jacqueline E Mann; Nicole L Michmerhuizen; Megan L Ludwig; Morgan M Sandelski; Christine M Komarck; Thomas E Carey; Mark E P Prince; Carol R Bradford; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Megan L Ludwig; Andrew C Birkeland; Rebecca Hoesli; Paul Swiecicki; Matthew E Spector; J Chad Brenner Journal: Cancer Biol Med Date: 2016-03 Impact factor: 4.248
Authors: Joshua D Smith; Andrew C Birkeland; Andrew J Rosko; Rebecca C Hoesli; Susan K Foltin; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Gregory T Wolf; Carol R Bradford; Mark E Prince; John Chad Brenner; Matthew E Spector Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: Janice L Farlow; Andrew C Birkeland; Andrew J Rosko; Kyle VanKoevering; Catherine T Haring; Joshua D Smith; J Chad Brenner; Andrew G Shuman; Steven B Chinn; Chaz L Stucken; Kelly M Malloy; Jeffrey S Moyer; Keith A Casper; Scott A McLean; Mark E P Prince; Carol R Bradford; Gregory T Wolf; Douglas B Chepeha; Matthew E Spector Journal: Ann Surg Oncol Date: 2019-03-04 Impact factor: 5.344
Authors: Jacqueline E Mann; Joshua D Smith; Andrew C Birkeland; Emily Bellile; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Jeffery S Moyer; Gregory T Wolf; Carol R Bradford; Mark E Prince; Thomas E Carey; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: Cancer Immunol Immunother Date: 2018-10-25 Impact factor: 6.968
Authors: Stephanie Flukes; Marc A Cohen; Louise M Cunningham; Richard J Wong; Jennifer R Cracchiolo Journal: J Surg Oncol Date: 2020-10-15 Impact factor: 3.454
Authors: Jacqueline E Mann; Aditi Kulkarni; Andrew C Birkeland; Judy Kafelghazal; Julia Eisenberg; Brittany M Jewell; Megan L Ludwig; Matthew E Spector; Hui Jiang; Thomas E Carey; J Chad Brenner Journal: Head Neck Date: 2019-05-15 Impact factor: 3.821
Authors: Christian Simon; Avinash Beharry; Vinidh Paleri; Pascaline Dübi; Karma Lambercy; F Christopher Holsinger; Jelena Todic Journal: Head Neck Date: 2022-06-02 Impact factor: 3.821